Evidence map›Paper›PMID 36328580›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.

Yumi Kosaka, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Yusuke Johira, Shigeki Yano, Kei Amioka, Kensuke Naruto and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Yumi KosakaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Tomokazu KawaokaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Masanari KosakaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Yuki ShiraneDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Ryoichi MiuraDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Serami MurakamiDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Yusuke JohiraDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Shigeki YanoDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Kei AmiokaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Kensuke NarutoDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Yuwa AndoDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Kenichiro KodamaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Shinsuke UchikawaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Hatsue FujinoDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Atsushi OhnoDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Takashi NakaharaDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Eisuke MurakamiDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Wataru OkamotoDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Masami YamauchiDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Michio ImamuraDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Hiroshi AikataDepartment of Gastroenterology and Metabolism, Hiroshima University Hospital, Japan.
Hiroshima University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To our knowledge, there have been no reports of first-line lenvatinib (LEN) and LEN re-challenge following atezolizumab/bevacizumab (Atezo-Bev) failure in the same patient. We herein report a patient with advanced hepatocellular carcinoma who failed either 1st line LEN and 2nd line Atezo-Bev, and successfully achieved complete response to LEN rechallenge with sequencial transcatheter arterial chemoembolization (TACE). This patient had a poor response to TACE before immunotherapy and introduction of molecular-targeted drugs but showed a good response to selective TACE after LEN rechallenge. Our findings suggest the need to reconsider the use of molecular-targeted drugs and TACE with advances in immunotherapy.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAntibodies, Monoclonal, HumanizedBevacizumabHumansPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, HumanizedatezolizumabBevacizumablenvatinibPhenylurea CompoundsQuinolinesatezolizumabbevacizumabhepatocellular carcinomalenvatinibTACE

Identifiers

PMID36328580
PMCPMC10332959
OpenAlexW4308010799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.